Indaptus Therapeutics, Inc. (INDP)
Health Care · Immunotherapy / Immuno-oncology · NASDAQ
A clinical-stage biotechnology company currently evaluating strategic options and potential business combinations to maximize shareholder value.
What Indaptus Therapeutics, Inc. does
Indaptus Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapies. The company's lead product candidate is Decoy20, which is currently in Phase 1 clinical trials with plans for multi-dosing and combination studies. Indaptus operates through a portfolio of research and development programs aimed at addressing unmet medical needs in cancer and other disease areas. As a clinical-stage enterprise with limited operating history, the company is not yet profitable and is dependent on raising additional capital to fund ongoing operations and development activities.
Themes: immuno-oncology, cancer immunotherapy, clinical-stage therapeutics, novel biologics
Fundamentals
- Price$1.14 as of 2026-08-26 close
- Market cap$152M as of 2026-08-26
- 1-year return-82.5% 2025-08-26 close $6.52 → 2026-08-26 close $1.14
- P/En/a earnings data not available
- ROE-454.0% as of 2026-08-27
- Debt / equity0.00 as of 2026-08-27
- Beta1.10 as of 2026-08-27
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How INDP compares in its sector
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-27
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Indaptus Therapeutics, Inc. looks technically
Indaptus Therapeutics, Inc. (INDP) is trading 49.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago. It is 86.7% below its highest point of the past year. Trading volume is unusually light — only about 35% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 49.1% below its 200-day average, the long-term trend line — a long-term downtrend | -49.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.21 | $2.21 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.24 | $2.24 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 2.4. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal | 1 session |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend) | 19.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 39.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($0.92 to $1.58) — its "stochastic" reading is 33 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 33.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.57 | $8.57 |
|---|---|---|
| From the 52-week high | it is 86.7% below its 52-week high (its highest price of the past year) | -86.7% |
| Above the 52-week low | it is 23.9% above its 52-week low (its lowest price of the past year) | +23.9% |
| Below the 52-week high | it is 86.7% below its highest point of the past year | 86.7% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $21952.00 (set on 2017-09-26) | $21952.00 |
| Given back of the 52-week move | over the past year its closes ranged ($0.936 to $6.52), and it has recovered only a small part of its fall from last year’s high — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.39 to $4.57. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.6% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 19.3% above a support level at $0.92 — a price it turned at twice since 2026-05-22, most recently on 2026-08-18. Since 2024-08-26 it has 1 such level below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -19.3% |
| All-time low | its lowest closing price on record is $0.92 (set on 2026-08-18) | $0.92 |
| Above the all-time low | it is 23.9% above its all-time low | +23.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 30th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2298 between its high and its low — about 20.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2298 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.89 and $1.47 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.89 – $1.18 – $1.47 |
| Typical daily range (% of price) | its price moves about 20.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 20.2% |
| Stretch from the 200-day average | it is trading 4.8 daily ranges below its 200-day average price (49.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 35% of its 30-day average | 0.35× |
|---|
Candlestick patterns
1
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-26 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 3.9% gap down opened on 2026-08-24 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 60.0 percentage points (the stock lost 56.3% while the market gained 3.7%) | -60.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 0.6 percentage points (the stock gained 2.7% while the market gained 2.1%) | +0.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 55.9 percentage points (the stock lost 44.7% while the market gained 11.1%) | -55.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 101.3 percentage points (the stock lost 82.5% while the market gained 18.7%) | -101.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 64% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 25.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -63.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 68% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.52 — a volume-weighted average of daily closes over 163 sessions, not a true tick-by-tick VWAP. | -67.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 68% below the average price paid since it last reported on 2026-03-17 (its 10-K), so the typical buyer over that stretch is under water. That average is $3.57 — a volume-weighted average of daily closes over 113 sessions, not a true tick-by-tick VWAP. | -68.0% |
Price levels it has turned at before
INDP last closed at $1.14 on 2026-08-26. Since 2024-08-26 it has turned at 1 price below its last close and 7 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.92 | Support | 19.3% below the last close | turned there twice · 2026-05-22 to 2026-08-18 |
| $1.65 | Resistance | 44.9% above the last close | turned there twice · 2025-11-21 to 2026-03-09 |
| $2.40 | Resistance | 111.0% above the last close | turned there twice · 2026-01-07 to 2026-07-08 |
| $2.93 | Resistance | 157.1% above the last close | turned there twice · 2025-12-09 to 2026-07-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $2.40.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $1.41 and $1.96 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-08-25.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["Clinical-stage company with substantial going concern doubts and no current profitability; dependent on successful capital raises to continue operations","Lengthy and uncertain clinical trial processes for Decoy20 and other candidates could result in delays, increased costs, or failure to achieve regulatory approval","Limited cash resources and need for additional capital raises may result in dilution to shareholders and potential loss of technology rights or product candidate commercialization rights"]
What changed in the latest 10-Q
AI-assisted comparison of INDP's 10-Q filed 2026-05-15 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 1-for-28 reverse stock split effective June 26, 2025
- Statement that in May 2025, the company decided to conclude enrollment in Decoy20 as monotherapy and focus on Combination Study
- Statement that the company has discontinued further enrollment in the Combination Study and there are no participants remaining
- Statement that the company does not have current plans to initiate a new clinical trial
- Discussion of strategic options evaluation for Post-Investment Transaction, including potential investment in or acquisition of target company
- Statement that investments in strategic options will be based on scientific validation, clinical and regulatory considerations, resource availability, and overall strategic planning
- Appointment of Joe Z. Tsien as scientific consultant in April 2026 to support evaluation of sleep-related biological signals, neurophysiological activity patterns, immune-therapeutic response pathways and functional physiological assessment methods
- Section on Impact of Macroeconomic Conditions describing effects of inflation and interest rates on financial markets and capital access
- Statement that as result of discontinued clinical trials, research and development expenses are expected to decrease in the short term
- Removed:
- Reference to 'Cautionary Note Regarding Forward-Looking Statements' section in forepart of Quarterly Report
- Reference to 'Summary Risk Factors' and Part II sections
- Phrase 'You should review the sections titled' regarding risk factors
- Reworded:
- Annual Report reference changed from 'year ended December 31, 2024 filed with the Securities and Exchange Commission on March 13, 2025' to 'year ended December 31, 2025 filed with the Securities and Exchange Commission on March 17, 2026'
- Cautionary note reference changed from directing reader to 'sections titled "Summary Risk Factors" and Part II' to directing reader to 'Cautionary Note Regarding Forward-Looking Statements section in the forepart of this Quarterly Report'
- Notes:
- Newer filing text appears truncated at end of Research and Development Expenses section ('...is unable to determine with any degree of certainty the duration and completio'), preventing full comparison of remainder of MD&A section
- Comparison limited to portions of MD&A that are present and readable in both filings
Risk Factors
- Added:
- Page number change: Item 1A Risk Factors moved from page 10 (older) to page 6 (newer)
- Page number change: Item 2 Unregistered Sales moved from page 10 (older) to page 6 (newer)
- Page number change: Item 3 Defaults Upon Senior Securities moved from page 10 (older) to page 6 (newer)
- Page number change: Item 4 Mine Safety Disclosures moved from page 10 (older) to page 6 (newer)
- Page number change: Item 5 Other Information moved from page 10 (older) to page 6 (newer)
- Page number change: Item 6 Exhibits moved from page 10 (older) to page 6 (newer)
- Reworded:
- Formatting change in SUMMARY RISK FACTORS section: Newer filing (2026-05-15) removed section page break indicator and shifted all bullet points to begin without 'ii' page marker present in older filing (2025-11-12)
- Notes:
- The text provided appears truncated at the end of both versions (older version ends mid-sentence with 'more eff'), preventing full comparison of complete risk factor content
- Substantive risk factor content is identical between the two filings up to the point where both texts end
- Primary observable differences are pagination/formatting rather than substantive content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for INDP — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
1 institutional 13F filer reported holding INDP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 1
- Reported shares held 39,018
- Reported value $71,013
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
INDP had 93,141 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
INDP had 0.07% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.06 days to cover at the same settlement.
- Reported short interest (shares) 93,141
- Short interest (% of shares outstanding) 0.07%
- Prior settlement (shares) 259,720
- Reported change -64.14%
- Days to cover (reported) 1.06
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INDP vs…
Indaptus Therapeutics, Inc. is found in…
Frequently asked questions
What does Indaptus Therapeutics, Inc. (INDP) do?
Indaptus Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapies. The company's lead product candidate is Decoy20, which is currently in Phase 1 clinical trials with plans for multi-dosing and combination studies. Indaptus operates through a portfolio of research and development programs aimed at addressing unmet medical needs in cancer and other disease areas.
What sector is Indaptus Therapeutics, Inc. (INDP) in?
Indaptus Therapeutics, Inc. (INDP) is classified in the Health Care sector. Its industry is Immunotherapy / Immuno-oncology. It trades on NASDAQ.
Who are Indaptus Therapeutics, Inc.'s (INDP) competitors?
Notable peers of Indaptus Therapeutics, Inc. (INDP) include Merck, Bristol Myers Squibb, Regeneron Pharmaceuticals and Nektar Therapeutics. This peer set is informational only — not financial advice.
Is Indaptus Therapeutics, Inc. (INDP) overbought or oversold right now?
Indaptus Therapeutics, Inc. (INDP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INDP come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.